File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Synthetic peptide studies on the Severe Acute Respiratory Syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development

TitleSynthetic peptide studies on the Severe Acute Respiratory Syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development
Authors
Issue Date2004
PublisherAmerican Association for Clinical Chemistry, Inc. The Journal's web site is located at http://www.clinchem.org
Citation
Clinical Chemistry, 2004, v. 50 n. 6, p. 1036-1042 How to Cite?
AbstractBackground: The S (spike) protein of the etiologic coronaviras (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach. © 2004 American Association for Clinical Chemistry.
Persistent Identifierhttp://hdl.handle.net/10722/172886
ISSN
2015 Impact Factor: 7.457
2015 SCImago Journal Rankings: 2.472
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChoy, WYen_US
dc.contributor.authorLin, SGen_US
dc.contributor.authorChan, PKSen_US
dc.contributor.authorTam, JSLen_US
dc.contributor.authorLo, YMDen_US
dc.contributor.authorChu, IMTen_US
dc.contributor.authorTsai, SNen_US
dc.contributor.authorZhong, MQen_US
dc.contributor.authorFung, KPen_US
dc.contributor.authorWaye, MMYen_US
dc.contributor.authorTsui, SKWen_US
dc.contributor.authorNg, KOen_US
dc.contributor.authorShan, ZXen_US
dc.contributor.authorYang, Men_US
dc.contributor.authorWu, YLen_US
dc.contributor.authorLin, ZYen_US
dc.contributor.authorNgai, SMen_US
dc.date.accessioned2012-10-30T06:25:34Z-
dc.date.available2012-10-30T06:25:34Z-
dc.date.issued2004en_US
dc.identifier.citationClinical Chemistry, 2004, v. 50 n. 6, p. 1036-1042en_US
dc.identifier.issn0009-9147en_US
dc.identifier.urihttp://hdl.handle.net/10722/172886-
dc.description.abstractBackground: The S (spike) protein of the etiologic coronaviras (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach. © 2004 American Association for Clinical Chemistry.en_US
dc.languageengen_US
dc.publisherAmerican Association for Clinical Chemistry, Inc. The Journal's web site is located at http://www.clinchem.orgen_US
dc.relation.ispartofClinical Chemistryen_US
dc.subject.meshAmino Acid Sequenceen_US
dc.subject.meshAnimalsen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshHaplorhinien_US
dc.subject.meshMembrane Glycoproteins - Chemistry - Immunologyen_US
dc.subject.meshMicroscopy, Confocalen_US
dc.subject.meshMicroscopy, Fluorescenceen_US
dc.subject.meshMolecular Sequence Dataen_US
dc.subject.meshPeptides - Chemical Synthesis - Chemistry - Immunologyen_US
dc.subject.meshRabbitsen_US
dc.subject.meshSars Virus - Immunologyen_US
dc.subject.meshVaccinationen_US
dc.subject.meshViral Envelope Proteins - Chemistry - Immunologyen_US
dc.subject.meshViral Vaccines - Immunologyen_US
dc.titleSynthetic peptide studies on the Severe Acute Respiratory Syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine developmenten_US
dc.typeArticleen_US
dc.identifier.emailNg, KO: ngko@hku.hken_US
dc.identifier.authorityNg, KO=rp01364en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1373/clinchem.2003.029801en_US
dc.identifier.pmid15044316-
dc.identifier.scopuseid_2-s2.0-2642575795en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-2642575795&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume50en_US
dc.identifier.issue6en_US
dc.identifier.spage1036en_US
dc.identifier.epage1042en_US
dc.identifier.isiWOS:000221873800008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChoy, WY=7006202379en_US
dc.identifier.scopusauthoridLin, SG=8689518400en_US
dc.identifier.scopusauthoridChan, PKS=7403497792en_US
dc.identifier.scopusauthoridTam, JSL=24788939600en_US
dc.identifier.scopusauthoridLo, YMD=7401935391en_US
dc.identifier.scopusauthoridChu, IMT=7103327448en_US
dc.identifier.scopusauthoridTsai, SN=8707094300en_US
dc.identifier.scopusauthoridZhong, MQ=7102458818en_US
dc.identifier.scopusauthoridFung, KP=7202934739en_US
dc.identifier.scopusauthoridWaye, MMY=7006687733en_US
dc.identifier.scopusauthoridTsui, SKW=7004961364en_US
dc.identifier.scopusauthoridNg, KO=21135553700en_US
dc.identifier.scopusauthoridShan, ZX=35277409800en_US
dc.identifier.scopusauthoridYang, M=35228247800en_US
dc.identifier.scopusauthoridWu, YL=8974511600en_US
dc.identifier.scopusauthoridLin, ZY=24166786700en_US
dc.identifier.scopusauthoridNgai, SM=7006074219en_US
dc.identifier.citeulike4085562-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats